View Financial HealthA SPAC III Acquisition 配当と自社株買い配当金 基準チェック /06AC III Acquisition配当金を支払った記録がありません。主要情報n/a配当利回り-246.7%バイバック利回り総株主利回り-246.7%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 29A SPAC III Acquisition Corp. Announces Notice of Non-Compliance with Nasdaq Listing RulesOn May 20, 2026, A SPAC III Acquisition Corp. (the Company) received a letter from The Nasdaq Stock Market LLC (Nasdaq), which stated that because the stockholders' equity of the Company reported on its Form 10-Q for the fiscal quarter ended March 31, 2026 was below the minimum of $2,500,000 stockholders' equity (the Minimum Stockholders' Equity Requirement) required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1), the Company no longer complies with Nasdaq's continued listing rules on The Nasdaq Capital Market. In accordance with the Nasdaq listing rules, the Company has 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant the Company an extension of up to 180 calendar days from the date of the letter to evidence compliance. The Company is currently working on a compliance plan and plans to submit it to Nasdaq within the specified period. There is no assurance that the Company will be able to regain compliance with the Minimum Shareholders' Equity Requirement or that its compliance plan will be accepted by Nasdaq.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$12.80, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 39x in the Capital Markets industry in the US. Total returns to shareholders of 27% over the past year.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$13.11, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 22x in the Capital Markets industry in the US. Total returns to shareholders of 31% over the past year.Board Change • Jan 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Jan 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$14.43, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 26x in the Capital Markets industry in the US. Total returns to shareholders of 45% over the past year.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to US$21.63, the stock trades at a trailing P/E ratio of 46.2x. Average trailing P/E is 26x in the Capital Markets industry in the US. Total returns to shareholders of 117% over the past year.Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$13.00, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 26x in the Capital Markets industry in the US.New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$24.5m market cap).Board Change • Aug 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 28Bioserica International Limited entered into a merger agreement to acquire A SPAC III Acquisition Corp. (NasdaqCM:ASPC) from A SPAC III (Holdings) Corp. and others for $200 million in a reverse merger transaction.Bioserica International Limited entered into a merger agreement to acquire A SPAC III Acquisition Corp. (NasdaqCM:ASPC) from A SPAC III (Holdings) Corp. and others for $200 million in a reverse merger transaction on May 23, 2025. Pursuant to the terms of the Merger Agreement, the aggregate consideration to be paid to existing shareholders and holders of equity awards of Bioserica is $200 million, which will be paid entirely in stock, comprised of newly issued Class B Ordinary Shares of the Purchaser at a price of $10.00 per share, plus such number of Purchaser Class A Ordinary Shares as determined pursuant to the Merger Agreement, up to a maximum of 1,786,000 Purchaser Class A Ordinary Shares. Upon the effectiveness of the Acquisition Merger, all issued and outstanding ordinary shares of Bioserica will be cancelled and automatically converted into the right to receive, without interest, the applicable number and class of the ordinary shares of the Purchaser. A SPAC III (Holdings) Corp., holder of the Parent’s Class B ordinary share, has at least one (1) demand registration right for its registrable securities. The deal is subject to regulatory approvals. Norton Rose Fulbright acted as legal advisor to Bioserica International, Loeb & Loeb LLP acted as legal advisor to A SPAC III Acquisition Corp.Board Change • Jan 06High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.決済の安定と成長配当データの取得安定した配当: ASPCの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ASPCの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場A SPAC III Acquisition 配当利回り対市場ASPC 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ASPC)n/a市場下位25% (US)1.4%市場トップ25% (US)4.1%業界平均 (Capital Markets)2.1%アナリスト予想 (ASPC) (最長3年)n/a注目すべき配当: ASPCは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ASPCは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ASPCの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ASPCが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/28 16:19終値2026/06/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋A SPAC III Acquisition Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 29A SPAC III Acquisition Corp. Announces Notice of Non-Compliance with Nasdaq Listing RulesOn May 20, 2026, A SPAC III Acquisition Corp. (the Company) received a letter from The Nasdaq Stock Market LLC (Nasdaq), which stated that because the stockholders' equity of the Company reported on its Form 10-Q for the fiscal quarter ended March 31, 2026 was below the minimum of $2,500,000 stockholders' equity (the Minimum Stockholders' Equity Requirement) required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1), the Company no longer complies with Nasdaq's continued listing rules on The Nasdaq Capital Market. In accordance with the Nasdaq listing rules, the Company has 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant the Company an extension of up to 180 calendar days from the date of the letter to evidence compliance. The Company is currently working on a compliance plan and plans to submit it to Nasdaq within the specified period. There is no assurance that the Company will be able to regain compliance with the Minimum Shareholders' Equity Requirement or that its compliance plan will be accepted by Nasdaq.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 19%After last week's 19% share price gain to US$12.80, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 39x in the Capital Markets industry in the US. Total returns to shareholders of 27% over the past year.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$13.11, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 22x in the Capital Markets industry in the US. Total returns to shareholders of 31% over the past year.
Board Change • Jan 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Jan 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$14.43, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 26x in the Capital Markets industry in the US. Total returns to shareholders of 45% over the past year.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to US$21.63, the stock trades at a trailing P/E ratio of 46.2x. Average trailing P/E is 26x in the Capital Markets industry in the US. Total returns to shareholders of 117% over the past year.
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improves as stock rises 24%After last week's 24% share price gain to US$13.00, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 26x in the Capital Markets industry in the US.
New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$24.5m market cap).
Board Change • Aug 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 28Bioserica International Limited entered into a merger agreement to acquire A SPAC III Acquisition Corp. (NasdaqCM:ASPC) from A SPAC III (Holdings) Corp. and others for $200 million in a reverse merger transaction.Bioserica International Limited entered into a merger agreement to acquire A SPAC III Acquisition Corp. (NasdaqCM:ASPC) from A SPAC III (Holdings) Corp. and others for $200 million in a reverse merger transaction on May 23, 2025. Pursuant to the terms of the Merger Agreement, the aggregate consideration to be paid to existing shareholders and holders of equity awards of Bioserica is $200 million, which will be paid entirely in stock, comprised of newly issued Class B Ordinary Shares of the Purchaser at a price of $10.00 per share, plus such number of Purchaser Class A Ordinary Shares as determined pursuant to the Merger Agreement, up to a maximum of 1,786,000 Purchaser Class A Ordinary Shares. Upon the effectiveness of the Acquisition Merger, all issued and outstanding ordinary shares of Bioserica will be cancelled and automatically converted into the right to receive, without interest, the applicable number and class of the ordinary shares of the Purchaser. A SPAC III (Holdings) Corp., holder of the Parent’s Class B ordinary share, has at least one (1) demand registration right for its registrable securities. The deal is subject to regulatory approvals. Norton Rose Fulbright acted as legal advisor to Bioserica International, Loeb & Loeb LLP acted as legal advisor to A SPAC III Acquisition Corp.
Board Change • Jan 06High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CEO, CFO & Chairman Claudius Tsang is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.